AltheaDx has added next-generation sequencing services to its clinical molecular pathology laboratory for applications in cancer biomarker discovery and clinical trial testing, the company said this week.
AltheaDx CEO Francois Ferre said in a statement that next-gen sequencing will be "highly synergistic" with the company's strategy of creating cancer-specific molecular subtype panels in partnership with Compendia Bioscience. In addition, the technology will be "highly complementary" to AltheaDx's RT-PCR-based gene expression panels.
The firm plans to provide pharmaceutical and biotechnology customers with well-characterized predictive biomarker panels of genetic polymorphisms and gene expression patterns.
Based in San Diego, AltheaDx develops and tests diagnostics. The company, which has GLP- and CLIA-certified laboratories, provides clinical biomarker discovery, assay development, and validation services.